Skip to main content

Table 1 Scale of OS and PFS curves in the immunotherapy combination group and chemotherapy group

From: Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach

Intervention

OS curve

PFS curve

Chemo

14.6

5.1

Sint-chemo

24.2

8.9

Pem-chemo

23.5

8.5

Nivo-ipi-chemo

21.8

7.0

Tisle-chemo

20.8

8.5

Camre-chemo

19.9

7.8

Nivo-ipi

19.7

6.1

Atezo-beva-chemo

20.0

10.3

Durva-treme-chemo

17.6

5.8

Atezo-chemo

17.4

7.2

Durva-treme

15.4

4.3